ArticleBMC pediatrics2025
Impact of patent ductus arteriosus treatment on neonatal outcomes in preterm infants with or without perinatal acidosis: a nationwide cohort study.
Article in BMC pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPerinatal acidosis is common in preterm infants and is associated with adverse short-term outcomes. However, its role in guiding the management of patent ductus arteriosus (PDA) remains unclear. This study aimed to evaluate the PDA treatment patterns and neonatal outcomes in preterm infants with and without perinatal acidosis.
methodsWe conducted a nationwide cohort study using the Korean Neonatal Network registry. Very low birth weight infants born before 30 weeks’ gestation between 2015 and 2021 were included. Perinatal acidosis was defined as a blood pH < 7.20 and a base deficit < 10 mEq/L within the first hour after birth. Multivariate logistic regression was used to evaluate the association between PDA treatment and neonatal outcomes stratified by acidosis status.
resultsAmong 6,158 infants, 441 (7.2%) experienced perinatal acidosis. The incidence of PDA and its treatment rates did not significantly differ between infants with and without perinatal acidosis. After adjusting for confounders, PDA treatment was associated with a significantly reduced risk of mortality, and the composite outcome of bronchopulmonary dysplasia (BPD) or death before 36 weeks’ postmenstrual age, irrespective of acidosis status. However, PDA treatment increased the risk of BPD in both groups.
conclusionsPDA treatment was associated with improved survival but increased BPD risk in preterm infants regardless of perinatal acid-base status. Perinatal acidosis should not be considered a contraindication to PDA treatment. These findings support individualized, physiology-guided PDA management in preterm infants.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.